Table 3.
Fire ground test performance data.
| Variable | Treatment | n | Mean | p-Value | ηp2 |
|---|---|---|---|---|---|
| Time-to-completion | PLA | 15 | 9.34 ± 1.42 | 0.966 | 0.000 |
| (min) | AX | 15 | 9.31 ± 1.91 | ||
| Total | 30 | 9.32 ± 1.66 | |||
| Air Tank Difference | PLA | 15 | 2,400 ± 382 | 0.829 | 0.002 |
| (PSI) | AX | 15 | 2,430 ± 373 | ||
| Total | 30 | 2,415 ± 371 | |||
| Air Extension Piece Difference | PLA | 15 | 2,343 ± 399 | 0.496 | 0.017 |
| (PSI) | AX | 15 | 2,437 ± 339 | ||
| Total | 30 | 2,390 ± 367 | |||
| Work Efficiency | PLA | 15 | 0.47 ± 0.14 | 0.986 | 0.000 |
| (lbs/in2/min) | AX | 15 | 0.48 ± 0.14 | ||
| Total | 30 | 0.47 ± 0.13 | |||
| Pre-FGT Heart Rate | PLA | 15 | 93.95 ± 19.31 | 0.817 | 0.002 |
| (bpm) | AX | 15 | 92.60 ± 11.51 | ||
| Total | 30 | 93.28 ± 15.63 | |||
| Post-FGT Heart Rate | PLA | 15 | 176.4 ± 11.3 | 1.000 | 0.000 |
| (bpm) | AX | 15 | 176.4 ± 7.6 | ||
| Total | 30 | 176.4 ± 9.5 | |||
| Top-of Stair Heart Rate | PLA | 15 | 179.3 ± 9.3 | 0.919 | 0.000 |
| (bpm) | AX | 15 | 178.9 ± 9.2 | ||
| Total | 30 | 179.1 ± 9.1 | |||
| Average Heart Rate | PLA | 15 | 158.8 ± 11.5 | 0.404 | 0.025 |
| (bpm) | AX | 15 | 154.9 ± 13.5 | ||
| Total | 30 | 156.8 ± 12.5 | |||
| Maximal Heart Rate | PLA | 15 | 181.3 ± 10.0 | 1.000 | 0.000 |
| (bpm) | AX | 15 | 181.3 ± 8.6 | ||
| Total | 30 | 181.3 ± 9.2 | |||
| Keiser Sled | PLA | 15 | 17.00 ± 3.95 | 0.127 | 0.081 |
| (# of hits) | AX | 15 | 15.13 ± 2.36 | ||
| Total | 30 | 16.07 ± 3.33 |
Data are expressed as means ± standard deviations for the placebo (PLA) and astaxanthin (AX) treatments. FGT = Fire Ground Test; PSI = Pounds Per Square Inch. Data were analyzed using a multivariate and univariate General Linear Model. P-levels, with partial ETA squared (ηp2) effect size, were reported. General Linear Model analysis revealed a nonsignificant overall Wilk’s Lambda for treatment (p = 0.873, ηp2 = 0.206) effect. ηp2 effect size values of 0.01–0.05 = small, 0.06–0.13 = medium, and > 0.14 = large.